Can I Take Vitamin D With Farxiga (Dapagliflozin)?

The Short Answer: No Dangerous Interaction Exists

Vitamin D and dapagliflozin do not compete for the same metabolic enzymes or transporters. Dapagliflozin is glucuronidated primarily by UDP-glucuronosyltransferase 1A9 (UGT1A9) in the liver and intestinal wall, producing an inactive 3-O-glucuronide metabolite that is renally excreted. Vitamin D3 (cholecalciferol) is hydroxylated first in the liver by CYP2R1 to 25-hydroxyvitamin D, then again in the kidney by CYP27B1 to its active form, 1,25-dihydroxyvitamin D (calcitriol). Because these two metabolic pathways are completely separate, neither drug accelerates nor inhibits the clearance of the other.

That separation means no dose adjustment, no staggered timing, and no ceiling on vitamin D dose that is caused by dapagliflozin itself. Your prescriber's decision about vitamin D dose depends on your serum 25(OH)D level, your kidney function, and your calcium balance, not on whether you take Farxiga.

Why the Question Gets Asked

Several forces push patients toward asking this question.

First, the FDA label for Farxiga carries a general caution about bone health, originating from early post-marketing signals in animal studies and an elevated fracture rate observed in one clinical program (CANVAS with canagliflozin, a different SGLT2 inhibitor). Patients reasonably wonder whether vitamin D, a well-known bone-protective nutrient, conflicts with that signal or amplifies it.

Second, clinicians routinely check vitamin D levels when starting Farxiga, particularly in CKD or T2D patients, so the two agents land in the same conversation even though they are not interacting. That timing creates an implicit association.

Third, a small subset of patients take calcitriol (active vitamin D) or alfacalcidol as prescription medications rather than over-the-counter cholecalciferol. The distinction matters clinically because calcitriol bypasses the kidney's activation step and can raise serum calcium, a parameter worth monitoring in anyone with CKD who is also losing glucose-bound water through SGLT2 blockade.

How Dapagliflozin Affects Bone and Calcium Physiology

The SGLT2 Mechanism and Mineral Metabolism

Dapagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, reducing glucose reabsorption and spilling roughly 70 grams of glucose per day into urine. This glycosuria is accompanied by osmotic diuresis: modest losses of water, sodium, and, to a lesser extent, calcium and phosphate. The net effect on mineral metabolism is small in most patients, but it is worth understanding mechanistically.

Chronic osmotic diuresis can raise serum parathyroid hormone (PTH) slightly, because the kidney senses volume contraction and adjusts calcium handling. Elevated PTH, if sustained, stimulates bone resorption to maintain serum calcium. A 2020 systematic review in the journal Bone found that SGLT2 inhibitors as a class produced small but measurable increases in bone turnover markers in some trials, though the clinical magnitude of that finding varied across individual agents. [1]

What DECLARE-TIMI 58 Actually Showed

The large cardiovascular outcomes trial DECLARE-TIMI 58 enrolled 17,160 adults with type 2 diabetes and either established cardiovascular disease or multiple risk factors, randomized to dapagliflozin 10 mg or placebo, and followed them for a median of 4.2 years. Fracture incidence in the dapagliflozin group was 4.6% versus 4.9% in the placebo group, a difference that was not statistically significant (P=0.35). [2]

This is the most definitive fracture dataset available specifically for dapagliflozin. The modest signal seen in earlier, smaller programs did not persist in this adequately powered trial.

Vitamin D's Role in the Bone Picture

Adequate vitamin D status (serum 25(OH)D above 20 ng/mL, with many endocrinology guidelines targeting 30 to 50 ng/mL) is necessary for intestinal calcium absorption and for restraining PTH secretion. If a Farxiga patient has undetected vitamin D deficiency, even the small PTH-stimulating effect of osmotic diuresis could push bone remodeling in a net-resorptive direction over years of treatment.

Correcting vitamin D deficiency, therefore, is a straightforward and evidence-supported step for anyone starting a long-term SGLT2 inhibitor regimen. The Endocrine Society's 2011 clinical practice guideline on vitamin D deficiency states: "We recommend that all adults who are vitamin D deficient be treated with 50,000 IU of vitamin D2 or vitamin D3 once a week for 8 weeks or its equivalent of 6,000 IU of vitamin D2 or vitamin D3 daily to achieve a blood level of 25(OH)D above 30 ng/mL." [3]

Vitamin D Deficiency in the Populations Who Take Farxiga

Type 2 Diabetes

Vitamin D deficiency is measurably more common in adults with type 2 diabetes than in the general population. A 2022 meta-analysis published in Nutrients (N=over 75,000 pooled participants) found that 58.3% of adults with type 2 diabetes had serum 25(OH)D below 20 ng/mL. [4] Low vitamin D correlates with insulin resistance through VDR-mediated effects on pancreatic beta-cell function and peripheral glucose uptake, creating an overlap between the condition dapagliflozin treats and the nutritional deficiency that vitamin D corrects.

Taking Farxiga does not cause vitamin D deficiency. The high background prevalence of deficiency in T2D patients simply means that screening and supplementation are clinically appropriate at the same time as SGLT2 inhibitor initiation.

Heart Failure

Dapagliflozin received FDA approval for heart failure with reduced ejection fraction (HFrEF) in 2020, based on the DAPA-HF trial (N=4,744), which showed a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001). [5] Adults with heart failure also carry high rates of vitamin D deficiency. A prospective cohort study published in the Journal of the American College of Cardiology found that 84% of HFrEF patients had 25(OH)D below 30 ng/mL. [6]

Whether vitamin D supplementation improves hard heart failure outcomes beyond what is achieved by correcting deficiency remains an open research question. VITAL-Heart Failure (a sub-study of the VITAL trial) found no significant reduction in major adverse cardiac events from high-dose vitamin D3 supplementation (2,000 IU/day) in a general population, though that study was not specifically powered for the HFrEF subgroup. [7]

Chronic Kidney Disease

CKD is perhaps the most important context for the vitamin D question in Farxiga patients. Dapagliflozin received FDA approval for CKD in 2021, based on the DAPA-CKD trial (N=4,304), which demonstrated a 39% relative risk reduction in the composite of sustained eGFR decline of at least 50%, end-stage kidney disease, or kidney or cardiovascular death (hazard ratio 0.61, 95% CI 0.51 to 0.72, P<0.001). [8]

CKD directly impairs vitamin D activation. As kidney function declines, CYP27B1 activity falls, reducing conversion of 25(OH)D to the active calcitriol. Patients with eGFR below 30 mL/min/1.73m2 may need prescription calcitriol or paricalcitol rather than over-the-counter cholecalciferol, because the kidney cannot complete the activation step. In that population, a prescriber should check not just 25(OH)D but also serum calcium, phosphate, and PTH before titrating vitamin D.

The critical practical distinction: cholecalciferol (OTC vitamin D3) requires two hydroxylation steps and is generally safe to take with Farxiga without special monitoring in patients with normal to mildly reduced kidney function. Calcitriol, which is already activated, carries hypercalcemia risk and requires more careful dose management, particularly in patients with CKD stage 3b or worse.

Pharmacokinetics in Detail: Why No Interaction Exists

The following framework describes the metabolic routing of both agents and confirms their independence. It can be used by clinical pharmacists during medication reconciliation for SGLT2 inhibitor patients.

Dapagliflozin metabolism:

• Absorbed orally, reaching peak plasma concentration (Tmax) at roughly 2 hours.
• Glucuronidated by UGT1A9 (major pathway) and CYP3A4 (minor pathway, less than 5% contribution).
• Primary inactive metabolite: dapagliflozin 3-O-glucuronide.
• Renal elimination of metabolites: approximately 75% of the dose recovered in urine.
• Plasma half-life: approximately 12.9 hours.
• No clinically meaningful effect from CYP2R1, CYP27B1, CYP24A1, or VDR-mediated gene expression.

Vitamin D3 (cholecalciferol) metabolism:

• Absorbed from the small intestine with dietary fat; lymphatic transport to liver.
• Hydroxylated in the liver by CYP2R1 to 25(OH)D3 (calcidiol).
• Second hydroxylation in the kidney by CYP27B1 to 1,25(OH)2D3 (calcitriol).
• Catabolized by CYP24A1, which is vitamin D-inducible and controlled by PTH and FGF-23.
• No interaction with UGT1A9. No competition for renal transporters used by dapagliflozin glucuronide.

No pharmacokinetic interaction has been described in the Farxiga prescribing information, the European Medicines Agency assessment report, or primary pharmacology studies. [9] The absence of interaction is not an absence of data; it is a mechanistically expected finding confirmed by the non-overlapping enzyme profiles of the two agents.

Practical Dosing and Monitoring Guidance

Vitamin D Dosing in Farxiga Patients

For patients with type 2 diabetes, heart failure, or CKD stage 1 to 3a (eGFR above 45 mL/min/1.73m2) taking dapagliflozin, the following approach reflects current evidence:

• Check serum 25(OH)D at Farxiga initiation if not measured in the past 12 months.
• If 25(OH)D is 12 to 20 ng/mL (deficient by most U.S. Guidelines), treat with 2,000 to 4,000 IU of vitamin D3 daily, or 50,000 IU weekly for 8 to 12 weeks, then recheck.
• If 25(OH)D is 20 to 30 ng/mL (insufficient), 1,000 to 2,000 IU daily of vitamin D3 is a reasonable maintenance dose.
• If 25(OH)D is above 50 ng/mL, supplementation is typically unnecessary unless a prescriber is treating a specific condition.
• Recheck serum 25(OH)D 3 months after starting a repletion regimen, then annually.

Calcium Supplementation: A Separate Consideration

Calcium and vitamin D are often co-prescribed for bone health. Calcium itself has no pharmacokinetic interaction with dapagliflozin either. However, calcium carbonate requires gastric acid for dissolution, so it should be taken with food. Calcium citrate does not require acid and can be taken at any time.

In patients with CKD stage 3b or worse (eGFR below 45 mL/min/1.73m2), hyperphosphatemia and secondary hyperparathyroidism require individualized management. Adding calcium supplements in that setting should be guided by a nephrologist.

When to Involve a Specialist

Patients who meet any of the following criteria should discuss vitamin D management with a nephrologist or endocrinologist rather than self-managing:

• eGFR below 30 mL/min/1.73m2.
• Serum PTH above 65 pg/mL.
• Serum calcium above 10.5 mg/dL.
• History of hypercalcemia or vitamin D toxicity.
• Already prescribed calcitriol, paricalcitol, or doxercalciferol.

What the Evidence Says About Vitamin D and Glycemic Control in T2D

A 2018 randomized controlled trial, the D-HEALTH trial (N=2,423 adults age 60 to 84), tested 60,000 IU of vitamin D3 monthly versus placebo and found no significant reduction in incident diabetes at 5 years. [10] This suggests that supraphysiologic supplementation in a general population does not prevent T2D progression.

However, the VITAL-Diabetes ancillary analysis showed a statistically significant 76% lower incidence of diabetes in adults with BMI <25 who received 2,000 IU of vitamin D3 daily versus placebo over 5.3 years (hazard ratio 0.24, 95% CI 0.11 to 0.54). [11] That interaction with BMI suggests that normal-weight individuals benefit most, while people already obese and already diabetic (the core Farxiga population) may see less glycemic benefit from vitamin D supplementation beyond deficiency correction.

The practical takeaway: supplementing to correct a documented deficiency is well-supported. Megadosing vitamin D to get extra glycemic benefit on top of dapagliflozin is not supported by current trial data.

Drug Interactions Farxiga Does Have: Putting Vitamin D in Context

Dapagliflozin does have real interactions that patients should know about. Listing them here helps clarify that vitamin D is not one of them.

• Loop diuretics (furosemide, bumetanide): combined use increases dehydration and hypotension risk. The DAPA-HF subgroup analysis showed that dapagliflozin added to loop diuretics in HFrEF patients maintained efficacy but required monitoring of volume status.
• Insulin and insulin secretagogues (sulfonylureas, meglitinides): dapagliflozin lowers glucose independently of insulin, so combining these agents raises hypoglycemia risk. The Farxiga FDA label recommends considering a dose reduction of the insulin or secretagogue when adding dapagliflozin. [9]
• Lithium: SGLT2 inhibitors increase renal lithium clearance in case reports; lithium levels should be monitored after starting dapagliflozin.
• UGT1A9 inducers (rifampin): can reduce dapagliflozin exposure by accelerating glucuronidation; clinical significance is modest.

Vitamin D at any standard supplemental dose, from 400 IU to 5,000 IU daily, does not appear in any of these interaction categories.

Summary of Clinical Recommendations

Adults taking Farxiga (dapagliflozin) for type 2 diabetes, heart failure, or CKD can take vitamin D supplements without pharmacokinetic concern. Baseline serum 25(OH)D testing is reasonable given the high prevalence of deficiency in these populations. In patients with CKD stage 3b or worse, kidney function limits conversion of cholecalciferol to calcitriol, so prescription-activated vitamin D forms may be necessary, managed by a specialist. The DECLARE-TIMI 58 trial (N=17,160) found no significant fracture excess with dapagliflozin over 4.2 years of follow-up, which means vitamin D supplementation in this context is a preventive measure against background deficiency risk, not a compensatory measure against drug-induced bone loss. Check your 25(OH)D level at your next Farxiga follow-up if it has not been measured in the past year.